the Rebuke

On Wednesday evening, December 4, 2025,‌ a group of twelve former Food and Drug Management (FDA)⁢ commissioners – representing over 35 years of collective leadership ⁤- issued ⁣a strong criticism of a recent internal⁢ memo authored by Dr. Peter Marks, the FDA’s Center for Biologics Evaluation and Research (CBER) director. ‍Their response, published in the new england Journal of Medicine, frames the memo as a “threat” to the​ FDA’s established processes ​and possibly harmful to public health.

The commissioners expressed being “deeply concerned” by the proposed changes, signaling a meaningful internal conflict within the agency.

The Policy Shift: From Immunobridging to Randomized Trials

Dr. Marks’⁣ memo proposes abandoning the FDA’s current practice of using‌ immunobridging​ studies to update seasonal vaccines, including those for influenza and COVID-19. Immunobridging assesses immune responses to new vaccine formulations, comparing them to those elicited by existing, approved vaccines. This ‌method ​allows for quicker updates⁣ based on ‌emerging variants.

Rather, Dr.Marks intends to mandate costly and time-consuming randomized controlled trials for ⁣each vaccine update. ‌These trials, which can take months or even years to complete,⁤ would significantly delay the availability⁣ of ⁤updated vaccines, potentially hindering the response to rapidly evolving viruses. ‌This ‌shift represents a substantial departure from established regulatory pathways.

Internal Dissent and Concerns About Openness

The memo also included ‍a directive that ⁣FDA ⁢staff who disagree with the proposed changes ⁢should submit their resignations.Moreover,‍ it reportedly characterizes voicing concerns or criticisms as “unethical” ‌and “illegal,” raising serious ​questions about internal freedom of expression and scientific debate within the agency. This aspect of the memo especially alarmed ⁤the former ⁢commissioners.

Commissioners’ Core Arguments

The former commissioners characterized Dr. Marks’ memo as “the⁤ latest in​ a series ⁢of troubling changes at the FDA” and deemed the⁤ proposed policy updates “not… coherent.” They argue that Dr.Marks’ criticisms of immunobridging‌ “misrepresent both the science and the⁢ regulatory record,” particularly for vaccines targeting well-understood pathogens with established ‍mechanisms of action. They emphasize the proven effectiveness and safety of immunobridging​ in past vaccine updates.

The commissioners’ ​letter underscores the importance of a flexible and responsive regulatory framework for vaccines, especially in the face of emerging infectious diseases. They suggest that the proposed changes could impede the FDA’s ability to ⁣protect public health effectively.

Who are the Former Commissioners?

While the specific names of the twelve former commissioners were not instantly released in initial ‌reports, their collective experience represents a⁤ significant weight of expertise in ⁢vaccine regulation and ⁢public health policy. Their unified response highlights the gravity of the situation and the potential consequences ⁢of the proposed changes.

Implications and Next Steps

This controversy raises critical questions about ⁣the future direction of vaccine regulation⁢ at the​ FDA. ‍The clash between current leadership and former commissioners suggests a essential disagreement over the balance between rigorous testing and rapid response in the context of evolving public‌ health threats. The situation is highly likely to prompt further debate ⁢within the agency and among public health experts. It remains to be‍ seen whether Dr. Marks ‌will reconsider ⁤his proposed policy changes considering the strong opposition from the former commissioners.